Uncategorised - European Medical Journal

Webinar: Solving the Puzzle of Recurrent Abdominal Pain

Professors Tacke and Cassiman will share their clinical experience of a disease often misdiagnosed or with delayed diagnosis.

Harnessing Healthcare’s Future

Michael Blackhurst, Founding Director, JTJ Services explores the value of self-reflection, the rise of NFTs in healthcare and much more.

Harvesting the Fruits of Pulmonary Disease Research: Learnings from the COVID-19 Pandemic

Prof. Felix Herth and Prof. Dave Singh discuss current and future plans of the EARCO research collaboration.

'Diagnosis, Treatment, Impact, and Unmet Needs of People with Mycosis Fungoides and Sézary Syndrome'?

Richard Cowan, oncologist and expert on cutaneous T-cell lymphomas, provides insights into both mycosis fungoides and sézary syndrome.

Dr Emma Roffe and Eric Low on combination treatments

Dr Emma Roffe, Takeda UK, and Eric Low, Myeloma UK, talk about the challenge of combination treatments.

Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesaemia: Is There a Best Replacement Strategy?

Over the past few decades, there have been important advances in cancer therapeutics, including a shift from traditional cytotoxic…

Latest News and Advancements Within the Areas of Axial Spondyloarthritis and Psoriatic Arthritis Featured at EULAR 2021

The chronic inflammatory diseases axial spondyloarthritis (AxS) and psoriatic arthritis (PsA) involve symptoms such as axial skeleton pain…

Two Subtypes of Metastatic Prostate Cancer Identified

Scientists have identified two subtypes of metastatic prostate cancer that responding differently to treatment.

Physical Activity Shows Evidence of Cancer Prevention in the USA

Engaging in 5 hours per week of moderate-intensity exercise could prevent 46,000 cancer cases annually in the USA.

Patient-Reported Outcomes with Monoclonal Antibody Therapies in Patients with Moderate-to-Severe Plaque Psoriasis

Richard B. Warren highlighted Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the Phase III BE VIVID trial in patients…